Simulation technology for diseases of the nervous system

Rhenovia Pharma SAS, a biotechnology company specialized in the development and optimization of treatments for diseases of the central and peripheral nervous system, announces today that it has signed a strategic partnership agreement with the French Muscular Dystrophy Association (Association Française contre les Myopathies – AFM). The two-year agreement is worth more than 500,000 Euros.

This strategic collaboration is aimed at speeding up the development of Rhenovia’s unique technology for simulating neuronal transmission and pushing ahead with experimental validation so as to be able to apply the technology faster. It will give AFM access to a speedier scientific approach for discovering and developing new pharmacological treatments for rare neurodegenerative diseases. This approach will also benefit pathologies that affect larger patient numbers, such as Alzheimer’s and Parkinson’s.